CD47 is highly expressed on tumor cells and aged red cells. This is recognised by SIRPα and represents a “don’t eat me” signal to prevent macrophage phagocytosis. Blocking this CD47 signal with magrolimab enhances macrophage phagocytosis of tumor and red cells, leading to potent anti-tumor activity and also the on-target toxicity of anemia.